Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allogene Therapeutics, Inc. (Nasdaq: ALLO) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Allogene files periodic reports and current reports that describe its AlloCAR T pipeline, financial condition, and key risks.
Among the most relevant filings for ALLO are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss clinical programs such as cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma, ALLO-329 in autoimmune disease, and ALLO-316 in renal cell carcinoma. These reports also include detailed risk factor sections covering topics like gene-editing technology, reliance on licensed TALEN-based platforms, and intellectual property disputes referenced in company disclosures.
Allogene also submits numerous current reports on Form 8-K to describe material events. Recent 8-K filings have furnished quarterly financial results, outlined changes to the ALPHA3 trial’s lymphodepletion regimen following safety review, and described third-party patent litigation involving Cellectis’s TALEN technology on which Allogene relies. Other filings document matters such as annual meeting voting results and the continued listing of ALLO common stock on The Nasdaq Stock Market LLC.
On Stock Titan, investors can use AI-powered tools to review these filings, surface key points, and understand how disclosures about clinical trial design, safety findings, intellectual property, and governance may relate to ALLO stock. The filings page is a central resource for tracking Allogene’s regulatory history, financial reporting, and formal statements about its allogeneic CAR T development strategy.
Allogene Therapeutics' Schedule 13G/A shows that David D. Chang, M.D., Ph.D., and related family trusts report combined beneficial ownership of 11,136,728 shares of common stock, representing 5.0% of the class. The filing states that this total includes 5,413,414 shares issuable upon exercise of options exercisable within 60 days, and breaks out voting and dispositive power as 8,223,532 shares sole and 2,913,196 shares shared. Separate trusts—the Chang 2006 Family Trust, JEC 2019 Trust and RTC 2019 Trust—report holdings of 1,201,108, 856,044 and 856,044 shares respectively, representing 0.5% and two 0.4% stakes. The percentage is calculated using 218,730,809 shares outstanding as disclosed by the issuer.
Insider Trading Alert: Allogene Therapeutics (ALLO) Director Vicki L. Sato received a significant stock option grant on June 18, 2025. The transaction details reveal:
- Granted 144,400 stock options to purchase common stock
- Exercise price set at $1.29 per share
- Options expire on June 18, 2035
- Vesting schedule: Equal monthly installments over 12 months
This Form 4 filing indicates a standard director compensation package through equity incentives. The relatively low exercise price and extended 10-year expiration term suggest a long-term alignment with shareholder interests. The monthly vesting schedule encourages continued service on the board. The transaction was executed directly, with no indirect ownership reported.
Allogene Therapeutics (ALLO) director Deborah M. Messemer received a significant equity grant on June 18, 2025. The insider was awarded 95,400 Restricted Stock Units (RSUs) with the following key terms:
- RSUs will vest in two equal semi-annual installments over one year from grant date
- Each RSU represents a right to receive one share of common stock
- Grant price was $0, as typical for RSU awards
- Director elected to defer receipt of shares until either:
- 30 days after Board separation
- Company change in control
This Form 4 filing represents standard non-employee director compensation and demonstrates continued alignment between board member and shareholder interests through equity-based compensation.
Franz B. Humer, Director at Allogene Therapeutics (ALLO), received a grant of 95,400 Restricted Stock Units (RSUs) on June 18, 2025. The RSUs represent the right to receive an equivalent number of common stock shares.
Key terms of the RSU grant:
- Vesting Schedule: Equal semi-annual installments over one year from grant date
- Exercise Price: $0
- Special Deferral: Humer elected to defer receipt of shares until either:
- 30 days after Board separation, or
- Company change in control
This Form 4 filing was submitted by Earl Douglas (Attorney-in-fact) on June 20, 2025, reporting the transaction under Section 16(a) of the Securities Exchange Act. The grant appears to be part of the company's Non-Employee Director Compensation Policy.
Elizabeth A. Barrett, Director of Allogene Therapeutics (ALLO), received a significant equity grant on June 18, 2025. The transaction involved the acquisition of 95,400 Restricted Stock Units (RSUs) with a $0 exercise price.
Key terms of the RSU grant:
- Vesting occurs in two equal semi-annual installments over one year from grant date
- Each RSU converts to one share of common stock
- Barrett elected to defer receipt of shares until either:
- 30 days after Board separation
- Company change in control
The grant represents part of the company's Non-Employee Director Compensation Policy. The filing was executed by Earl Douglas as Attorney-in-Fact on June 20, 2025.
Allogene Therapeutics (ALLO) director Stephen Mayo received a significant equity grant on June 18, 2025, consisting of 95,400 Restricted Stock Units (RSUs). The RSUs will vest in two equal semi-annual installments over a one-year period from the grant date.
Key terms of the RSU grant:
- Each RSU represents one share of common stock
- Grant price: $0
- Mayo elected to defer receipt of shares until either:
- 30 days after Board separation
- Company change in control
This Form 4 filing, executed by Earl Douglas as attorney-in-fact on June 20, 2025, reflects standard non-employee director compensation practices. The grant strengthens Mayo's alignment with shareholder interests through increased equity ownership.
Director Joshua A. Kazam of Allogene Therapeutics (ALLO) received a grant of 94,500 Restricted Stock Units (RSUs) on June 18, 2025. This represents a significant equity compensation award for the board member.
Key details of the RSU grant:
- Each RSU converts to one share of common stock
- Vesting occurs in two equal semi-annual installments over one year from grant date
- Exercise price is $0
- Vesting is contingent on continued service as director
The filing was reported via Form 4 on June 20, 2025, within the required two-business-day window for insider transaction reporting. The transaction represents a direct ownership position and was executed pursuant to the company's director compensation program.
Allogene Therapeutics (Nasdaq: ALLO) filed a Form 8-K reporting the voting results of its 2025 Annual Meeting of Stockholders held on June 18, 2025.
- Director elections: Stockholders re-elected Elizabeth Barrett (131,435,760 FOR), Arie Belldegrun M.D. (150,891,245 FOR) and David Chang M.D. Ph.D. (153,721,017 FOR) as Class I directors, each to serve until the 2028 annual meeting. Broker non-votes totaled 33,512,034 shares.
- Executive compensation: The non-binding advisory vote approved the compensation of named executive officers with 139,947,868 FOR versus 14,233,309 AGAINST and 3,184,237 abstentions.
- Auditor ratification: Ernst & Young LLP was confirmed as independent registered public accounting firm for fiscal 2025 with 190,111,256 FOR and only 414,604 AGAINST.
No other items were presented. The filing contains no updates on financial performance, strategic initiatives, or legal matters.